The features of TROP2 overexpression on the surface of tumor cells and vulnerability to PARP inhibitors suggest a combination therapy strategy using anti‐TROP2 antibody–drug conjugates (ADC) and PARP inhibitors. This evidence concerns the gene TACSTD2 and neoplasm.